Semaglutide for Treating Paediatric Craniopharyngioma‐Related Obesity: A Multicentre Case Series
Authors' conclusion
Semaglutide was associated with reversal of weight gain among adolescents with craniopharyngioma-related obesity.
Study context
- Population
- Patients <18 years with craniopharyngioma and obesity (BMI >2 WHO Z-score), 2019–2024; at initiation age 14.0 ± 3.9 years, BMI 33.4 ± 3.9 kg/m²; all with GH and TSH deficiencysource population 139
- Participants
- 20 patients
- Exposure
- BMI change in the year after semaglutide initiation vs the year before
- Outcome
- Within-patient comparison of BMI change from −12 months to treatment initiation and from initiation to +12 months
- Follow-up
- 12 months
Methodological detailsmulticentre, within-patient comparison
- Multicentre
- Within-patient comparison
Main finding
As reported in the abstract
BMI change
Before semaglutide
3.5
SD 4.4 · kg/m²
Semaglutide
−2.5
SD 3.9 · kg/m²
P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Before treatment | Semaglutide | P value |
|---|---|---|---|
| BMI Z-score change (gain in year before treatment; loss after 1 year of semaglutide) · 12 monthsPaired comparison · within-patient paired comparison | 0.6 (SD 1.6) BMI Z-score gained | 0.5 (SD 0.5) BMI Z-score lost | P = 0.004 |
BMI decrease ≥10% during treatment
- Proportion of patients with BMI decrease of 10% or more during treatment
- 40% (95% CI: 19%-64%)
Safety
Adverse events
- Gastrointestinal side effects (mild)
- 30%
- Treatment discontinuation, pituitary insufficiency decompensation or tumour recurrence
- 0
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Semaglutide for Treating Paediatric Craniopharyngioma‐Related Obesity: A Multicentre Case Series. Diabetes Obes Metab. Published 28 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →